Ascentage Pharma Group International Inc. announced the pricing of 22 million shares at HKD68.60 per share in an offshore transaction, expected to close on July 17, 2025. The Company will issue 22 million new ordinary shares to the Vendor at the same price after the Offshore Placement. The net proceeds from the Placement will be used for commercialization efforts, global clinical development, and infrastructure. The Placement Shares have not been registered under the Securities Act and cannot be offered or sold in the United States. Ascentage Pharma is a biopharmaceutical company focused on cancer treatments, with a pipeline of innovative drug candidates.

Read more at GlobeNewswire: Ascentage Pharma Announces Pricing of Top-Up Placement